TABLE 2.
Changes in CMAP amplitude decrement at baseline and 12 months in 11 patients undergoing low-frequency RNS.
| Variable | Baseline (%) | 12 months (%) | p-value |
|---|---|---|---|
| (n = 11) | (n = 11) | ||
| Predominant nerve decrement | 25.0 (20.0, 27.0) | 14.0 (11.0, 17.0) | 0.003 |
| Mean three-nerve decrement | 15.3 (11.3, 16.3) | 9.3 (7.3, 11.7) | 0.003 |
P-values from Wilcoxon signed-rank tests comparing baseline vs. 12 months.